Drug Profile
Desvenlafaxine - extended release - Alembic
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Alembic
- Developer Sun Pharmaceutical Industries
- Class Amines; Antidepressants; Cyclohexanols; Phenols; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Major depressive disorder
Most Recent Events
- 25 Mar 2015 Sun Pharmaceutical Industries acquires Ranbaxy
- 08 May 2013 Launched for Major depressive disorder in USA (PO)
- 05 Mar 2013 Registered for Major depressive disorder in USA (PO)